Short term heart rate variability is preserved in Parkinson’s disease under atomoxetine
Clicks: 1
ID: 327830
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #129 of 130 articles by views in Brain communications
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 130 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Repurposed noradrenergic drugs have been proposed to treat neuropsychiatric symptoms in Parkinson’s disease and related conditions. While there is evidence that these drugs can be beneficial for cognition in selected patients, questions remain about their cardiovascular effects. Here we tested whether heart rate variability (HRV) is altered in people with Parkinson’s disease, following a single-dose challenge with the noradrenaline reuptake inhibitor atomoxetine (40 mg, oral). Consistent with previous work, our cohort of people with idiopathic Parkinson’s disease (n=15) had lower HRV than healthy controls (n=22). Decreased HRV in people with Parkinson’s disease was associated with reduced integrity of the caudal locus coeruleus, measured using neuromelanin-sensitive ultra-high field 7T magnetic resonance imaging. Following a randomised double-blind placebo-controlled crossover challenge in the Parkinson’s disease group, short-term resting HRV was not significantly altered following atomoxetine. Using Bayesian statistical inference, we demonstrated confidence in the preservation of HRV across measures in the time, frequency, and non-linear domains. Our findings are in favour of a safe cardiovascular profile for atomoxetine in Parkinson’s disease, further supporting noradrenergic modulation as a viable treatment strategy for neuropsychiatric symptoms in Parkinson’s disease and related disorders.
| Reference Key |
openalex_W7138323934
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Isabella F Orlando, Frank H. Hezemans, Kamen A. Tsvetanov, Rong Ye, Catarina Rua, Ralf Regenthal, Roger A. Barker, Caroline Williams-Gray, Luca Passamonti, Trevor Robbins, James Rowe, Claire O’Callaghan |
| Journal | Brain communications |
| Year | 2026 |
| DOI |
10.1093/braincomms/fcag338
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.